There are currently 669 clinical trials in Milwaukee, Wisconsin looking for participants to engage in research studies. Trials are conducted at various facilities, including Medical College of Wisconsin, Childrens Hospital of Wisconsin, Aurora Saint Luke's Medical Center and Aurora Sinai Medical Center. Whether you're a healthy volunteer looking to participate in paid medical research or seeking trials related to a specific condition, the city provides a diverse range of opportunities near you.
An Evaluation of the AeriSeal System for CONVERTing Collateral Ventilation Status in Patients With Severe Emphysema
NCT06035120
Recruiting
This is a prospective, open-label, multi-center, single-arm study planned to enroll 200 subjects with heterogeneous emphysema and collateral ventilation (CV) in the target lobe. Subjects will undergo instillation of AeriSeal Foam in the target lobe and subsequent assessment of CV status using Chartis Pulmonary Assessment System. Subjects with CV- status will then undergo placement of Zephyr Valve in the target lobe for bronchoscopic lung volume reduction (BLVR) and be followed for 24 months.
Gender:
ALL
Ages:
Between 40 years and 80 years
Trial Updated:
05/28/2025
Locations: Medical College of Wisconsin (MCW), Milwaukee, Wisconsin
Conditions: Emphysema, Pulmonary, Emphysema or COPD
Register for Updates
Testing the Addition of the Drug Relugolix to the Usual Radiation Therapy for Advanced-Stage Prostate Cancer, The NRG Promethean Study
NCT05053152
Recruiting
This phase II trial compares the usual treatment of radiation therapy alone to using the study drug, relugolix, plus the usual radiation therapy in patients with castration-sensitive prostate cancer that has spread to limited other parts of the body (oligometastatic). Relugolix is in a class of medications called gonadotropin-releasing hormone (GnRH) receptor antagonists. It works by decreasing the amount of testosterone (a male hormone) produced by the body. It may stop the growth of cancer cel... Read More
Gender:
MALE
Ages:
18 years and above
Trial Updated:
05/28/2025
Locations: Aurora Saint Luke's Medical Center, Milwaukee, Wisconsin +2 locations
Conditions: Oligometastatic Prostate Carcinoma, Prostate Adenocarcinoma, Stage IVB Prostate Cancer AJCC v8, Prostate Ductal Adenocarcinoma, Prostate Intraductal Carcinoma
Register for Updates
The GORE® VIAFORT Vascular Stent Iliofemoral Study
NCT05489588
Recruiting
This study is a prospective, non-randomized, multicenter, single-arm, clinical study to evaluate the performance, safety and efficacy of the GORE® VIAFORT Vascular Stent for treatment of symptomatic iliofemoral venous obstruction.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/28/2025
Locations: Medical College of Wisconsin - Froedtert Hospital, Milwaukee, Wisconsin
Conditions: Venous Thromboses, Venous Disease, Venous Leg Ulcer, Venous Stasis, Venous Ulcer, Venous Stenosis, Venous Occlusion, Vein Thrombosis, Vein Occlusion, Vein Disease
Register for Updates
AZD0486 as Monotherapy in B-cell Acute Lymphoblastic Leukaemia
NCT06137118
Recruiting
This is a Phase 1/2, global multicentre, open-label, single-arm, dose escalation and dose optimisation study of AZD0486 to evaluate the safety, tolerability, and efficacy of AZD0486 monotherapy in participants with R/R B ALL who have received ≥ 2 prior lines of therapies. The study will consist of 3 parts. Part A monotherapy dose escalation. Part B dose optimisation. Part C Dose expansion at the recommended phase 2 dose (RP2D)
Gender:
ALL
Ages:
12 years and above
Trial Updated:
05/28/2025
Locations: Research Site, Milwaukee, Wisconsin
Conditions: B-cell Acute Lymphoblastic Leukemia (B-ALL)
Register for Updates
Study Evaluating Safety and Efficacy of JCAR017 in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL)
NCT03331198
Recruiting
This is a Phase 1/2, open-label, multicenter study to determine the efficacy and safety of JCAR017 in adult subjects with relapsed or refractory CLL or SLL. The study will include a Phase 1 part to determine the recommended dose of JCAR017 monotherapy in subjects with relapsed or refractory CLL or SLL, followed by a Phase 2 part to further assess the efficacy and safety of JCAR017 monotherapy treatment at the recommended dose. A separate Phase 1 cohort will assess the combination of JCAR017 and... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/28/2025
Locations: Froedtert Hospital BMT Medical College of Wisconsin, Milwaukee, Wisconsin +1 locations
Conditions: Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, Small Lymphocytic
Register for Updates
A Study of Vedolizumab With and Without Upadacitinib in Adults With Crohn's Disease
NCT06227910
Recruiting
The main aim of this study is to learn whether vedolizumab and upadacitinib given together (also called dual targeted therapy or DTT) reduces bowel inflammation and ulcers in the bowel compared to vedolizumab only (also called monotherapy) in adults with moderately or severely active Crohn's Disease (CD) after 12 weeks of treatment. Other aims are to learn how safe and effective DTT is compared to monotherapy for these participants. All participants will receive DTT (either vedolizumab and upad... Read More
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
05/28/2025
Locations: Medical College of Wisconsin Cancer Center - Froedtert Hospital, Milwaukee, Wisconsin
Conditions: Crohn's Disease
Register for Updates
Efficacy/Safety of ALTB-268 in Subjects w/Moderately to Severely Active UC Refractory to Biologics
NCT06109441
Recruiting
ALTB-268-201 is a Phase 2a, multicenter, single arm, multiple-dose, open-label study evaluating the efficacy and safety of ALTB-268 in subjects with moderately to severely active UC. The study consists of a Screening Phase, an Induction Phase, a Maintenance Phase, and an OLE.
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
05/28/2025
Locations: Wisconsin Center for Advanced Research, Milwaukee, Wisconsin
Conditions: Ulcerative Colitis
Register for Updates
Phase III Study of Rilvegostomig in Combination With Bevacizumab With or Without Tremelimumab as First-line Treatment of Hepatocellular Carcinoma
NCT06921785
Recruiting
This is a Phase III, randomised, open-label, sponsor-blinded, 3-arm, multicentre, global study assessing the efficacy and safety of rilvegostomig in combination with bevacizumab with or without tremelimumab compared to atezolizumab in combination with bevacizumab. This study will be conducted in participants with advanced HCC who are not amenable to curative therapy or locoregional therapy
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/28/2025
Locations: Research Site, Milwaukee, Wisconsin
Conditions: Hepatocellular Carcinoma
Register for Updates
Efficacy and Safety of Tozorakimab in Patients Hospitalised for Viral Lung Infection Requiring Supplemental Oxygen
NCT05624450
Recruiting
The purpose of this study is to evaluate the effect of tozorakimab, as an add-on to SoC in patients with viral lung infection requiring supplemental oxygen, on the prevention of death or progression to IMV/ECMO.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/27/2025
Locations: Research Site, Milwaukee, Wisconsin
Conditions: Viral Lung Infection and Acute Respiratory Failure
Register for Updates
HLA-Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation With Reduced Dose Post Transplantation Cyclophosphamide GvHD Prophylaxis
NCT06001385
Recruiting
The goal of this clinical trial is to determine the effectiveness of Reduced Dose Post-Transplant Cyclophosphamide (PTCy) in patients with hematologic malignancies after receiving an HLA-Mismatched Unrelated Donor (MMUD) . The main question\[s\] it aims to answer are: * Does a reduced dose of PTCy reduce the occurrence of infections in the first 100 days after transplant? * Does a reduced dose of PTCy maintain the same level of protection against Graft Versus Host Disease (GvHD) as the standard... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/27/2025
Locations: Froedtert & the Medical College of Wisconsin, Milwaukee, Wisconsin
Conditions: Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Acute Leukemia, Myelodysplastic Syndromes, Chronic Myeloid Leukemia, Chronic Lymphocytic Leukemia, Myeloproliferative Neoplasm, Lymphoma, Chronic Myelomonocytic Leukemia, Pro-Lymphocytic Leukemia, Myelofibrosis
Register for Updates
Prehospital Analgesia INtervention Trial (PAIN)
NCT05437575
Recruiting
The Prehospital Analgesia INtervention trial (PAIN) is a proposed 4 year (3-year enrollment) multicenter, prehospital, randomized, double-blind, clinical trial that will enroll approximately 994 patients at select LITES Network sites. The objective is to perform a prospective, interventional, randomized trial among prehospital trauma patients with compensated shock (SI≥0.9) and an indication for pain management, comparing patient centered outcomes following prehospital administration of ketamine... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/27/2025
Locations: Medical College of Wisconsin, Milwaukee, Wisconsin
Conditions: Traumatic Injury
Register for Updates
BLOCK-SAH - PPF-Block for Post-SAH Headache
NCT06008795
Recruiting
BLOCK-SAH is a phase II, multicenter, randomized, double-blinded, placebo-controlled clinical trial with a sequential parallel comparison design (SPCD) of bilateral pterygopalatine fossa (PPF) injections with 20mg ropivacaine + 4mg dexamethasone (active, PPF-block) compared to saline (placebo) for headache in survivors of aneurysmal subarachnoid hemorrhage (SAH), while monitoring intracranial arterial mean flow velocities with transcranial Doppler (TCD) peri-intervention (intervention = PPF-inje... Read More
Gender:
ALL
Ages:
Between 18 years and 85 years
Trial Updated:
05/27/2025
Locations: Medical College of Wisconsin, Milwaukee, Wisconsin
Conditions: Subarachnoid Hemorrhage, Aneurysmal, Headache
Register for Updates